Screener
Mirum Pharmaceuticals, Inc. MIRM Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeBenefitsAndShareBasedCompensation.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of sales (excluding intangible amortization) | 23,663 | 17,527 | 45,783 | 34,651 |
| General and administrative expenses (excluding stock-based compensation) | 17,378 | 13,090 | 36,553 | 24,771 |
| Commercialization and Medical Affairs expenses (excluding stock-based compensation) | 48,204 | 39,590 | 92,422 | 75,372 |
| Research and development expenses (excluding stock-based compensation) | 76,301 | 38,443 | 150,022 | 74,258 |
| Acquired IPR&D | 16,435 | — | 742,737 | 5,000 |
| Stock-based compensation | 30,114 | 18,230 | 87,240 | 33,702 |
| Intangible amortization | 6,685 | 5,894 | 13,370 | 11,788 |
| Loss from operations | $(42,537) | $(4,989) | $(832,002) | $(20,172) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp?
- Mirum Pharmaceuticals, Inc. (MIRM) reported business segments — stock-based comp of $30.11M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp increased by 65.2% year-over-year, from $18.23M to $30.11M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp?
- Over 3 years (2022 to 2025), Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp has grown at a 37.5% compound annual growth rate (CAGR), from $27.01M to $70.25M.
- What does business segments — stock-based comp mean?
- Measures the non-cash expense recognized for equity-based awards granted to employees and executives. This metric is essential for understanding the total cost of human capital and the potential dilution impact on existing shareholders.
Ask your AI about Mirum Pharmaceuticals, Inc.'s business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude